Sir, Combination of peripheral laser photocoagulation with intravitreal bevacizumab in naïve eyes with macular edema secondary to CRVO: prospective randomized study Increased vascular endothelial growth factor (VEGF) production has been reported in central retinal vein occlusion (CRVO), which could be due to peripheral retinal ischemia. 1 Panretinal laser photocoagulation (PLP) in peripheral retina has been shown to reduce the VEGF production. 2 Here, we report 1-year results of a prospective randomized single-masked trial comparing 1.25 mg intravitreal bevacizumab pro-re-nata (PRN) monotherapy and PRN therapy in combination with PLP at 1 month in treatment of naive eyes with macular edema (ME) secondary to CRVO.
Naive eyes with center-involving ME secondary to CRVO of o9 months duration, minimum central subfield thickness (CST) of 250 μm on spectral domain optical coherence tomography, and best-corrected visual acuity of 24-73 letters were included. Subjects were randomized to either monotherapy or combination group. Through month 12, subjects were evaluated monthly and treated with intravitreal injections on a PRN basis as per predefined retreatment criteria. Seven field fluorescein angiography and electroretinography (ISCEV standards) were performed at baseline, month 6 and month 12. Wilcoxon signed-rank test was performed to evaluate changes in visual acuity and CST.
Twenty-two eyes of 21 consecutive subjects were enrolled. Baseline characteristics of both groups are shown as Table 1 . Mean change in visual acuity in monotherapy and combination group at the last visit from baseline was 24.61 (P = 0.001) and 25.49 (P = 0.001) letters, respectively (P = 0.32). Mean decrease in CST in monotherapy and combination group at the last visit from baseline was 515 ± 202 (P = 0.0002) and 642 ± 224 (P = 0.0003) microns, respectively (P = 0.3) (Figure 1 ). Mean number of injections in monotherapy and combination group was 6.0 ± 3.17 and 6.7 ± 3.59, respectively (P = 0.33). There was no significant difference in b/a ratio on ERG between two groups.
Spaide 3 reported outcome of 10 eyes, which underwent peripheral laser photocoagulation during the treatment with ranibizumab. He reported no difference in the number of injections (3.4 vs 3.1) 6 months before and after peripheral laser photocoagulation. Similar to our results, RETAIN and RELATE trials also reported no benefits of PLP. 4, 5 In conclusion, early PLP in eyes with CRVO neither shows additional benefits on functional outcome nor to reduce the number of injections during the 1-year follow-up. 
